An adult elephant has the body mass of about 100 human beings. Despite their enormous size, these remarkable creatures defy the odds by almost never getting cancer.
This paradox is still a mystery to scientists. It’s also a source of inspiration for a promising new Wisconsin spinoff company, Elephas Biosciences, which has created a platform to predict whether patients will respond successfully to cancer immunotherapy.
Elephas was born in 2020 with major influences from bioimaging advances at the University of Wisconsin–Madison and the Morgridge Institute for Research. Morgridge Investigator Kevin Eliceiri, a UW–Madison professor of medical physics and biomedical engineering, has been working closely with Elephas leaders to help bring this promising new technology to fruition.
Read the full story here: https://morgridge.org/story/new-cancer-imaging-startup-harnesses-wisconsin-expertise/